Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. STKE, 2 August 2005
Vol. 2005, Issue 295, p. pe39
[DOI: 10.1126/stke.2952005pe39]

PERSPECTIVES

How Will RNAi Facilitate Drug Development?

Steven Bartz* and Aimee L. Jackson*

Rosetta Inpharmatics, LLC., a wholly owned subsidiary of Merck & Co., Inc., 401 Terry Avenue North, Seattle, WA 98109, USA.

Abstract: Development of effective drugs for treatment of human disease relies on identification of therapeutic molecular targets. The identification of targets to treat human disease has previously relied on genetic screens in model organisms, and less robust or lower throughput approaches in mammalian systems. RNA interference (RNAi) makes possible, for the first time, the use of large-scale functional genomics approaches for target identification in human cells. This remarkable breakthrough has the potential to influence every facet of the drug discovery process, and is poised to revolutionize drug development. Reports of RNAi screens for the identification of novel genes implicated in apoptosis, cell division, and drug resistance support the enormous promise of this technology. Here, we discuss the potential impact of RNAi screens on target identification and validation and consider issues that warrant caution when interpreting RNAi screening results.

*Corresponding authors. E-mail: steven_bartz{at}merck.com, aimee_jackson{at}merck.com

Citation: S. Bartz, A. L. Jackson, How Will RNAi Facilitate Drug Development? Sci. STKE 2005, pe39 (2005).

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Permissive and restricted virus infection of murine embryonic stem cells.
R. Wash, S. Calabressi, S. Franz, S. J. Griffiths, D. Goulding, E.-P. Tan, H. Wise, P. Digard, J. Haas, S. Efstathiou, et al. (2012)
J. Gen. Virol. 93, 2118-2130
   Abstract »    Full Text »    PDF »
Experimental validation of the importance of seed complement frequency to siRNA specificity.
E. M. Anderson, A. Birmingham, S. Baskerville, A. Reynolds, E. Maksimova, D. Leake, Y. Fedorov, J. Karpilow, and A. Khvorova (2008)
RNA 14, 853-861
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882